ILMN Illumina, Inc.

  1. Stocks
  2. Healthcare
  3. NASDAQ: ILMN

Price (delayed)

$353.53

Market cap

$51.97B

P/E Ratio

55.24

Dividend/share

N/A

EPS

$6.4

Enterprise value

$51.82B

Sector: Healthcare
Industry: Diagnostics & Research
Website: http://www.illumina.com
Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina segment, which serves customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. The firm's products include microarray scanners, sequencing reagents, and onsite training selector. Its services include sequencing and microarray services; proactive instrument monitoring; and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Highlights

Illumina's debt has decreased by 25% YoY
The equity has increased by 16% YoY
The quick ratio has contracted by 40% from the previous quarter but it has grown by 10% YoY
ILMN's net income is up by 11% year-on-year but it is down by 6% since the previous quarter
The stock's price to earnings (P/E) is 14% more than its last 4 quarters average of 48.6 and 8% more than its 5-year quarterly average of 51.1

Key stats

What are the main financial stats of ILMN
Market
Shares outstanding
147M
Market cap
$51.97B
Enterprise value
$51.82B
Valuations
Price to earnings (P/E)
55.24
Price to book (P/B)
11.21
Price to sales (P/S)
14.61
EV/EBIT
46.52
EV/EBITDA
39.9
EV/Sales
14.57
Earnings
Revenue
$3.56B
EBIT
$1.11B
EBITDA
$1.3B
Free cash flow
$941M
Per share
EPS
$6.4
Free cash flow per share
$6.4
Book value per share
$31.53
Revenue per share
$24.19
TBVPS
$42.85
Balance sheet
Total assets
$7.26B
Total liabilities
$2.63B
Debt
$1.85B
Equity
$4.64B
Working capital
$3.27B
Liquidity
Debt to equity
0.4
Current ratio
4.1
Quick ratio
3.61
Net debt/EBITDA
-0.11
Margins
EBITDA margin
36.5%
Gross margin
70.4%
Net margin
26.5%
Operating margin
27.3%
Efficiency
Return on assets
13.2%
Return on equity
20.9%
Return on invested capital
20.9%
Return on capital employed
17.9%
Return on sales
31.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ILMN stock price

How has the Illumina stock price performed over time

Financial performance

How have Illumina's revenue and profit performed over time
Revenue
$3.56B
Gross profit
$2.5B
Operating income
$970M
Net income
$942M
Gross margin
70.4%
Net margin
26.5%
The operating income has increased by 12% YoY
ILMN's net income is up by 11% year-on-year but it is down by 6% since the previous quarter
The company's gross profit rose by 7% YoY
Illumina's operating margin has increased by 7% YoY

Valuation

What is Illumina stock price valuation
P/E
55.24
P/B
11.21
P/S
14.61
EV/EBIT
46.52
EV/EBITDA
39.9
EV/Sales
14.57
The stock's price to earnings (P/E) is 14% more than its last 4 quarters average of 48.6 and 8% more than its 5-year quarterly average of 51.1
Illumina's EPS has increased by 11% YoY but it has decreased by 6% QoQ
The equity has increased by 16% YoY
The price to book (P/B) is 8% higher than the last 4 quarters average of 10.4
ILMN's P/S is 22% above its 5-year quarterly average of 12.0 and 9% above its last 4 quarters average of 13.4
Illumina's revenue has increased by 4.7% YoY

Efficiency

How efficient is Illumina business performance
The ROE has contracted by 11% YoY and by 10% from the previous quarter
Illumina's return on sales has decreased by 6% QoQ but it has increased by 5% YoY
The company's return on assets fell by 5% QoQ but it rose by 4.8% YoY
ILMN's return on invested capital is down by 4.6% since the previous quarter and by 4.1% year-on-year

Dividends

What is ILMN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ILMN.

Financial health

How did Illumina financials performed over time
The total assets is 177% more than the total liabilities
The quick ratio has contracted by 40% from the previous quarter but it has grown by 10% YoY
The current ratio has contracted by 39% from the previous quarter but it has grown by 12% YoY
Illumina's debt is 60% lower than its equity

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.